CompletedPHASE2, PHASE3NCT03920228
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
Studying Pachyonychia congenita
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Palvella Therapeutics, Inc.
- Principal Investigator
- David Hansen, MDUniversity of Utah
- Intervention
- PTX-022(drug)
- Enrollment
- 73 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2020
Study locations (9)
- Arizona Research Center, Phoenix, Arizona, United States
- Stanford University, Palo Alto, California, United States
- Yale University, New Haven, Connecticut, United States
- International Dermatology Research, Miami, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- Minnesota Clinical Study Center, Fridley, Minnesota, United States
- Oregon Health and Science University, Portland, Oregon, United States
- Paddington Testing Co., Philadelphia, Pennsylvania, United States
- University of Utah, Murray, Utah, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03920228 on ClinicalTrials.govOther trials for Pachyonychia congenita
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05643872A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia CongenitaPalvella Therapeutics, Inc.
- RECRUITINGNCT02321423International Pachyonychia Congenita Research RegistryPachyonychia Congenita Project